Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization. (Q53675901)

From Wikidata

Jump to navigation Jump to search

scientific article published in July 2005

Language	Label	Description	Also known as
English	Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization.	scientific article published in July 2005

Statements

scholarly article

1 reference

Europe PubMed Central

17 May 2018

http://europepmc.org/abstract/MED/15894362

Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization. (English)

1 reference

Europe PubMed Central

17 May 2018

http://europepmc.org/abstract/MED/15894362

immunohistochemistry

1 reference

based on heuristic

inferred from title

papillary carcinoma

1 reference

based on heuristic

inferred from title

author name string

Alessandro D Santin

1

1 reference

Europe PubMed Central

17 May 2018

http://europepmc.org/abstract/MED/15894362

Stefania Bellone

2

1 reference

Europe PubMed Central

17 May 2018

http://europepmc.org/abstract/MED/15894362

Sue Van Stedum

3

1 reference

Europe PubMed Central

17 May 2018

http://europepmc.org/abstract/MED/15894362

Wendy Bushen

4

1 reference

Europe PubMed Central

17 May 2018

http://europepmc.org/abstract/MED/15894362

Luis E De Las Casas

5

1 reference

Europe PubMed Central

17 May 2018

http://europepmc.org/abstract/MED/15894362

Soheila Korourian

6

1 reference

Europe PubMed Central

17 May 2018

http://europepmc.org/abstract/MED/15894362

Erming Tian

7

1 reference

Europe PubMed Central

17 May 2018

http://europepmc.org/abstract/MED/15894362

Juan J Roman

8

1 reference

Europe PubMed Central

17 May 2018

http://europepmc.org/abstract/MED/15894362

Alexander Burnett

9

1 reference

Europe PubMed Central

17 May 2018

http://europepmc.org/abstract/MED/15894362

Sergio Pecorelli

10

1 reference

Europe PubMed Central

17 May 2018

http://europepmc.org/abstract/MED/15894362

language of work or name

0 references

publication date

1 July 2005

1 reference

Europe PubMed Central

17 May 2018

http://europepmc.org/abstract/MED/15894362

Gynecologic Oncology

1 reference

Europe PubMed Central

17 May 2018

http://europepmc.org/abstract/MED/15894362

98

1 reference

Europe PubMed Central

17 May 2018

http://europepmc.org/abstract/MED/15894362

1

1 reference

Europe PubMed Central

17 May 2018

http://europepmc.org/abstract/MED/15894362

24-30

1 reference

Europe PubMed Central

17 May 2018

http://europepmc.org/abstract/MED/15894362

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

Endometrial papillary serous carcinoma: patterns of spread and treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

Uterine papillary serous carcinoma: patterns of metastatic spread

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

Role of HER receptors family in development and differentiation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

HER-2/neu expression: a major prognostic factor in endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

Uterine papillary serous adenocarcinoma. A 10-case study of p53 and c-erbB-2 expression and DNA content

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

HER-2/neu amplification and overexpression in endometrial carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

Her-2/neu overexpression and amplification in uterine papillary serous carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

Racial differences in survival of women with endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

Theories of endometrial carcinogenesis: a multidisciplinary approach

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

HER-2 gene amplification can be acquired as breast cancer progresses

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

Structural determinants of the interaction between the erbB2 receptor and the Src homology 2 domain of Grb7

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2005.03.041

7 January 2021

Identifiers

10.1016/J.YGYNO.2005.03.041

1 reference

Europe PubMed Central

17 May 2018

http://europepmc.org/abstract/MED/15894362

1 reference

Europe PubMed Central

17 May 2018

http://europepmc.org/abstract/MED/15894362

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53675901&oldid=1524503006"